CD45RA-depleted DLI for the Prevention of Viral Infections in High-risk Patients After Haploidentical Transplantation
Trial statusNot yet recruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age14-50
SponsorRuijin Hospital
About this trial
The goal of this clinical trial is to learn whether giving patients a special type of donor immune cells (called CD45RA Depleted DLI) can help prevent viral infections after a stem cell transplant. It will also learn about the safety of this treatment. The main questions it aims to answer are:
Does this treatment lower the chance of getting serious viral infections after transplant? What medical problems do patients have when receiving this treatment?
Eligibility criteria
Qualifiers
Patients undergoing allogeneic hematopoietic stem cell transplantation (any conditioning regimen or graft source is allowed).
Age ≥50 years or ≤14 years
Non-sibling matched transplantation
In vivo or ex vivo T-cell depletion
Disqualifiers
Active grade II-IV acute graft-versus-host disease (aGVHD)
Active aGVHD requiring prednisone or equivalent corticosteroid >0.5 mg/kg/day
Active viral infection
Uncontrolled or relapsed malignancy
Trial design
Treatments tested in this trial
- CD45RA-depleted DLI
Treatment groups
30 Participants
are divided into 1 treatment groupSponsors and collaborators
Ruijin Hospital
Lead sponsor
Shanghai Liquan Hospital
Collaborator
Source ClinicalTrials.gov